Cargando…

Clinical predictors of therapeutic response to antipsychotics in schizophrenia

The search for clinical outcome predictors for schizophrenia is as old as the field of psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors, only very few clinically useful outcome predictors have been identified. The goal of future treatment is to either affe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carbon, Maren, Correll, Christoph U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Les Laboratoires Servier 2014
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336920/ https://www.ncbi.nlm.nih.gov/pubmed/25733955

Ejemplares similares

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA
por: Galling, Britta, et al.
Publicado: (2018)

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
por: Loebel, Antony, et al.
Publicado: (2015)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
por: Tiihonen, Jari, et al.
Publicado: (2019)

Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics
por: Correll, Christoph U., et al.
Publicado: (2022)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
por: Kane, John M., et al.
Publicado: (2021)

Comparative effectiveness of antipsychotic drugs in schizophrenia
por: Stroup, T. Scott, et al.
Publicado: (2000)

The Therapeutic Relationship and Adherence to Antipsychotic Medication in Schizophrenia
por: McCabe, Rosemarie, et al.
Publicado: (2012)

Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs
por: Bossie, Cynthia A., et al.
Publicado: (2015)

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

Predictors of switching antipsychotic medications in the treatment of schizophrenia
por: Nyhuis, Allen W, et al.
Publicado: (2010)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
por: Correll, Christoph U., et al.
Publicado: (2022)

Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review
por: CORRELL, Christoph U., et al.
Publicado: (2016)

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
por: Litman, Robert, et al.
Publicado: (2023)

Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics
por: Chen, Yi-Lung, et al.
Publicado: (2018)

Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review
por: Coles, Alexandria S., et al.
Publicado: (2021)

The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research
por: Potkin, Steven G., et al.
Publicado: (2020)

Association between Serum Cortisol and DHEA-S Levels and Response to Antipsychotic Treatment in Schizophrenia
por: Babinkostova, Zoja, et al.
Publicado: (2015)

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
por: Citrome, Leslie, et al.
Publicado: (2013)

Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery
por: Arango, Celso, et al.
Publicado: (2023)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic, Martha, et al.
Publicado: (2018)

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2005)

Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study
por: Mitchell, Alex J., et al.
Publicado: (2019)

Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial
por: Long, Yujun, et al.
Publicado: (2023)

The heterogeneity of antipsychotic response in the treatment of schizophrenia
por: Case, M., et al.
Publicado: (2011)

Patterns and predictors of oral antipsychotic prescribing in adult patients with schizophrenia
por: Vadiei, Nina, et al.
Publicado: (2022)

Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: Treatment goals and approaches to functional recovery
por: Arango, Celso, et al.
Publicado: (2023)

Pharmacologic treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2010)

Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
por: Correll, Christoph U, et al.
Publicado: (2020)

Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs
por: Kucharska-Pietura, Katarzyna, et al.
Publicado: (2012)

Antipsychotic effects on anthropometric outcomes in anorexia nervosa: a retrospective chart review of hospitalized children and adolescents
por: Frank, Bettina, et al.
Publicado: (2023)

Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials
por: Pagsberg, A K, et al.
Publicado: (2014)

The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach
por: Correll, Christoph U., et al.
Publicado: (2022)

Polymorphisms in Schizophrenia-Related Genes Are Potential Predictors of Antipsychotic Treatment Resistance and Refractoriness
por: Zazueta, Alejandra, et al.
Publicado: (2022)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
por: Correll, Christoph U, et al.
Publicado: (2019)

O7.2. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION IN A CLINICAL COHORT
por: Rubio, Jose, et al.
Publicado: (2018)

Mortality risk of antipsychotic augmentation for adult depression
por: Gerhard, Tobias, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4uaekperj1uj4gnuebodsj117i